| Range: | 4.42-18.4 | Vol Avg: | 166056 | Last Div: | 0 | Changes: | 0.01 |
| Beta: | -0.76 | Cap: | 0.39B | Currency: | USD | Exchange: | NASDAQ |
| Sector: | Healthcare | IPO: | Tue Feb 01 2022 | Empoloyees: | 31 | ||
| CUSIP: | CIK: | 0001100663 | ISIN: | CA29286M1059 | Country: | CA | |
| CEO: | Mr. Ronald H. W. Cooper | Website: | https://www.engene.com | ||||
ENGN 7.70 Stock Price enGene Holdings Inc. Common Stock
enGene Holdings Inc., through its subsidiary enGene, Inc., operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin. The company was founded in 2023 and is based in Saint-Laurent, Canada.
Stock Details
About The Monevue
The content provided on this site is for informational purposes only and does not constitute financial, investment, or professional advice. We are not registered investment advisors or financial planners, and we do not provide recommendations or advice on buying, selling, or holding any particular stocks or securities. Any investment decisions should be made based on your own research and consultation with a qualified financial professional. We are not responsible for any financial loss or damages incurred from reliance on the information provided on this site. Please invest responsibly and seek professional advice when needed.
• Powered by StackThrow